{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T13:35:18Z","timestamp":1767706518932,"version":"3.38.0"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2024,8,7]],"date-time":"2024-08-07T00:00:00Z","timestamp":1722988800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,8,7]],"date-time":"2024-08-07T00:00:00Z","timestamp":1722988800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur Child Adolesc Psychiatry"],"published-print":{"date-parts":[[2025,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>The COVID-19 pandemic was associated with increases in the prevalence of depression and anxiety among children and young adults. We studied whether the pandemic was associated with changes in prescription benzodiazepine use. We conducted a population-based study of benzodiazepine dispensing to children and young adults\u2009\u2264\u200924 years old between January 1, 2013, and June 30, 2022. We used structural break analyses to identify the pandemic month(s) when changes in prescription benzodiazepine dispensing occurred, and interrupted time series models to quantify changes in dispensing following the structural break and compare observed and expected benzodiazepine use. A structural break occurs where there is a sudden change in the trend of a time series. We observed an immediate decline in benzodiazepine dispensing of 23.6 per 100,000 (95% confidence interval [CI]: -33.6 to -21.2) associated with a structural break in April 2020, followed by a monthly decrease in the trend of 0.3 per 100,000 (95% CI: -0.74 to 0.14). Lower than expected benzodiazepine dispensing rates were observed each month of the pandemic from April 2020 onward, with relative percent differences ranging from \u2212\u20097.4% (95% CI: -10.1% to \u2013 4.7%) to -20.9% (95% CI: -23.2% to -18.6%). Results were generally similar in analyses stratified by sex, age, neighbourhood income quintile, and urban versus rural residence. Further research is required to understand the clinical implications of these findings and whether these trends were sustained with further follow-up.<\/jats:p>","DOI":"10.1007\/s00787-024-02531-6","type":"journal-article","created":{"date-parts":[[2024,8,7]],"date-time":"2024-08-07T08:03:11Z","timestamp":1723017791000},"page":"791-794","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Brief Report: A population-based study of the impact of the COVID-19 pandemic on benzodiazepine use among children and young adults"],"prefix":"10.1007","volume":"34","author":[{"given":"Tony","family":"Antoniou","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathleen","family":"Pajer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William","family":"Gardner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melanie","family":"Penner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yona","family":"Lunsky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"McCormack","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mina","family":"Tadrous","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muhammad","family":"Mamdani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Gozdyra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David N.","family":"Juurlink","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tara","family":"Gomes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,8,7]]},"reference":[{"key":"2531_CR1","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1001\/jamapediatrics.2021.2482","volume":"175","author":"N Racine","year":"2021","unstructured":"Racine N, McArthur BA, Cooke JE, Eirich R, Zhu J, Madigan S (2021) Global prevalence of depressive and anxiety symptoms in children and adolescents during COVID-19: a Meta-analysis. JAMA Pediatr 175:1142\u20131150","journal-title":"JAMA Pediatr"},{"key":"2531_CR2","doi-asserted-by":"publisher","first-page":"104169","DOI":"10.1016\/j.brat.2022.104169","volume":"157","author":"DA Chavira","year":"2022","unstructured":"Chavira DA, Ponting C, Ramos G (2022) The impact of COVID-19 on child and adolescent mental health and treatment considerations. Behav Res Ther 157:104169","journal-title":"Behav Res Ther"},{"key":"2531_CR3","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1016\/j.jad.2022.11.068","volume":"323","author":"M Tiger","year":"2023","unstructured":"Tiger M, Wesselhoeft R, Karlsson P et al (2023) Utilization of antidepressants, anxiolytics, and hypnotics during the COVID-19 pandemic in Scandinavia. J Affect Disord 323:292\u2013298","journal-title":"J Affect Disord"},{"key":"2531_CR4","first-page":"1","volume":"15","author":"TJ Campbell","year":"2023","unstructured":"Campbell TJ, Men S, Shearer D et al (2023) The epidemiology of benzodiazepine-related toxicity in Ontario, Canada: a population-based descriptive study. Can J Public Health 15:1\u201311","journal-title":"Can J Public Health"},{"key":"2531_CR5","unstructured":"Canadian Institute for Health Information (2024) Canadian COVID-19 Intervention Timeline \u2014 Data Tables. https:\/\/www.cihi.ca\/en\/canadian-covid-19-intervention-timeline. Accessed April 15"},{"key":"2531_CR6","unstructured":"Han JY, Breton C (2024) Have provinces put students first during COVID? https:\/\/policyoptions.irpp.org\/magazines\/february-2022\/have-provinces-put-schools-first-during-covid\/. Accessed April 15"},{"key":"2531_CR7","doi-asserted-by":"publisher","first-page":"e216298","DOI":"10.1001\/jamapediatrics.2021.6298","volume":"176","author":"NR Saunders","year":"2022","unstructured":"Saunders NR, Kurdyak P, Stukel TA et al (2022) Utilization of Physician-Based Mental Health Care Services among Children and adolescents before and during the COVID-19 pandemic in Ontario, Canada. JAMA Pediatr 176:e216298","journal-title":"JAMA Pediatr"},{"key":"2531_CR8","doi-asserted-by":"publisher","first-page":"47","DOI":"10.2307\/2998540","volume":"66","author":"J Bai","year":"1998","unstructured":"Bai J, Perron P (1998) Estimating and testing linear models with multiple structural changes. Econometrica 66:47\u201378","journal-title":"Econometrica"},{"key":"2531_CR9","doi-asserted-by":"publisher","first-page":"730915","DOI":"10.3389\/fpsyt.2021.730915","volume":"12","author":"SL Stewart","year":"2021","unstructured":"Stewart SL, Vasudeva AS, Van Dyke JN, Poss JW (2021) Following the epidemic waves: child and Youth Mental Health Assessments in Ontario through multiple pandemic waves. Front Psychiatry 12:730915","journal-title":"Front Psychiatry"},{"key":"2531_CR10","doi-asserted-by":"publisher","first-page":"1282845","DOI":"10.3389\/fped.2023.1282845","volume":"11","author":"T Antoniou","year":"2023","unstructured":"Antoniou T, Pajer K, Gardner W et al (2023) Impact of the COVID-19 pandemic on antidepressant and antipsychotic use among children and adolescents: a population-based study. Front Pediatr 11:1282845. https:\/\/doi.org\/10.3389\/fped.2023.1282845","journal-title":"Front Pediatr"}],"container-title":["European Child &amp; Adolescent Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00787-024-02531-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00787-024-02531-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00787-024-02531-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,27]],"date-time":"2025-02-27T07:19:12Z","timestamp":1740640752000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00787-024-02531-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,7]]},"references-count":10,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["2531"],"URL":"https:\/\/doi.org\/10.1007\/s00787-024-02531-6","relation":{},"ISSN":["1018-8827","1435-165X"],"issn-type":[{"type":"print","value":"1018-8827"},{"type":"electronic","value":"1435-165X"}],"subject":[],"published":{"date-parts":[[2024,8,7]]},"assertion":[{"value":"10 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 July 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 August 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"ICES is an independent, non-profit research institute whose legal status under Ontario\u2019s health information privacy law allows it to collect and analyze health care and demographic data, without consent, for health system evaluation and improvement. ICES is a prescribed entity under Sect.\u00a045 of Ontario\u2019s Personal Health Information Protection Act. Section\u00a045 authorizes ICES to collect personal health information, without consent, for the purpose of analysis or compiling statistical information with respect to the management of, evaluation or monitoring of, the allocation of resources to or planning for all or part of the health system. Projects conducted under Sect.\u00a045, by definition, are exempt from and do not require review by a Research Ethics Board. This project was conducted under Sect.\u00a045 and approved by ICES\u2019 Privacy and Compliance Office.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Melanie Penner has received consulting fees for unrelated work from the Government of Nova Scotia. Mina Tadrous has received consulting fees for unrelated work from Green Shield Canada and the Canadian Agency for Drugs and Technologies in Health. Tara Gomes has received funding from the Ontario MOH and the Ontario College of Pharmacists.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}